proteonova™ inc. overview © 2008 proteonova™, inc
TRANSCRIPT
ProteoNova™ Inc.
Overview
© 2008 ProteoNova™, Inc.
The Company
ProteoNova is a biotechnology company located in Pasadena, California.
The Company has developed a platform technology that ….
.… accelerates the development of novel proteins for therapeutic and diagnostic uses, and ….
…. has broad applications – including for humans, livestock, and crop plants.
Next
The Company has patented novel methods that….
…. use a proprietary DNA library….
…. link proteins with their coding messages….
…. use accelerated protein evolution and specialized selection techniques….
…. to rapidly and inexpensively make novel protein products.
The Technology
Next
Potential Markets
• Human Pharmaceuticals
• Vaccines• Diagnostics• Veterinary Drugs
• Biowarfare• Agriculture• Enzymes • Industrial Chemicals
Next
The technology can be used to develop products in the following categories:
How the Technology Works
An illustration of the Company’s overall approach for generating novel proteins….
Next
Protein Evolution in Practice
DNA Library
ProteoNova Selection
Technologies
Translated mRNA pool
Enrichedand selected
cDNAs TranslatedProtein
OptimizeSelected cDNAs
by error prone PCR
Test for functionalactivity
Next
5’
ProteoNova’s Proprietary DNA Library
3’Linker
• The reading frame of the oligos in the library is random.
• The library is extremely large, > 1x1014 different sequences.
• It is biased to produce hydrophilic proteins.
• The library produces proteins ~100 amino acids long.
• The sequences in the library are labeled with a light activatable linker.
Next
360nm Light activates the linker, and thereby, crosslinks the mRNA with the ultimate tRNA
The modified mRNA occupies the last codon and accepts the protein thus forming an mRNA-tRNA-Protein complex
Light activatablecross linker on last codon of the mRNAs from proprietary DNA library
The Linker Technology
Next
5’3’
5’
Protein
tRNA
mRNA
Complex
5’Puromycin
Ribosome
In Vitro transcription/
translation
ProteoNova’s Various Linker Methods
Puromycin on 3’
Linker on anticodon
Linker on anticodon
Linker on mRNA
Puromycin on 3’
Linker on mRNA
Complex360 nmirradiation
In vitro translationMethods
Next
Real time PCR of cDNA
TaqDNA
Polymerase
TaqDNA
Polymerase
Reverse transcribe mRNA to cDNA using reverse transcriptase,
nucleotides and primers
c-DNA
N
S
Protein-tRNA-mRNA complexes reacted
with Target molecule affixed to solid substrate, i.e..
magnetic beads
Transcribe/translate the library using ProteoNova’s
linker technology
Protein-tRNA-mRNA complex
Selection Process
5’ 3’linker
DNA Library
Next
Purify the protein and configure for
preclinical testing
Introduce the DNA into host cells or
organism
Target molecule
Bioreactor culture
Rnd 1 Rnd 3Rnd 2 Rnd 1 Rnd 2
0 1 2 3 4 5 6 7 8 9
Months
Transcribe/translate library
• select for product• make enough for testing • test in vitro• a viable product expected
within three rounds of selection
Product that tests efficacious in vitro is then tested in vivo in animal model(s)
• a viable product expected within two rounds of selection
In vitro testing
Phase IIn vivo testing in animals
Phase II
Pre-clinical testing
Pre-Clinical Testing
Next
Intellectual Property
Three U.S. patents have been issued
Six patent applications are pending in the U.S.
The Company has a patent issued in Australia, and patents pending in the EU, Japan, Hong Kong and Canada
The ProteoNova, Inc. name is trademarked in the U.S. and is a registered trademark in the EU
Next
Summary
It dramatically reduces the time, labor and cost for producing proteins with specific properties.
The system can be used to create effective vaccines, more sensitive and specific diagnostics, and virtually any therapeutic where antibodies are currently used.
The technology is protected with a broad patent portfolio.
ProteoNova’s technology is a powerful platform technology that harnesses the power of accelerated protein evolution and in vitro mRNA and tRNA display to greatly simplify production of novel proteins.
Next
Contact Information
For further information, please direct queries to:
Robert Guerrero, Ph.D.CEOProteoNova, Inc.814 South Euclid AvenuePasadena, California 91106
Telephone: 626-793-9970Facsimile: 626-795-2599E-mail: [email protected]
ProteoNova™ Inc.